TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28902065

Group type: EXPERIMENTAL
Intervention: Emotional Regulation (ER) intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Health Promotion (HP) condition
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Low unsupervised time
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: High unsupervised time
Number of subjects: 420
Study: 25943669

Group type: EXPERIMENTAL
Intervention: COLD (evaporative and conductive cooling)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: COOL (evaporative cooling)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CONT (no precooling)
Number of subjects: 10
Study: 23832433

Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of curcumin and fluoxetine
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (Curcumin, Fluoxetine, Combination)
Number of subjects: 60
Study: 22122292

Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 488
Study: 19152106

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) activated (ON)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) inactivated (OFF)
Number of subjects: 839
Study: 17803013

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 15521935

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) technique
Number of subjects: 557

Group type: COMPARATOR
Intervention: Conventional rectal cancer surgery
Number of subjects: 557
Study: 11476413

Group type: EXPERIMENTAL
Intervention: 1.5 mg of intravenous midazolam
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 34
Study: 9738557

Group type: EXPERIMENTAL
Intervention: Wide excision plus isolated limb perfusion (ILP) with melphalan and mild hyperthermia
Number of subjects: 832

Group type: COMPARATOR
Intervention: Wide excision only
Number of subjects: 832
Study: 8036822

Group type: EXPERIMENTAL
Intervention: Four vaccine doses at months M0, M1, M2 and M12
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Three vaccine doses at M0, M1 and M6
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Three vaccine doses at M0, M1 and M12
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: One or two doses
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Overall vaccination with CHO‐recombinant vaccine
Number of subjects: 582
Study: 29924719

Group type: EXPERIMENTAL
Intervention: SAP group (progressive strengthening, agility training, plyometrics)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: SAP + PERT group (SAP with perturbation training)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 79
Study: 27221952

Group type: EXPERIMENTAL
Intervention: Bedtime hypertension treatment strategy
Number of subjects: 18078

Group type: EXPERIMENTAL
Intervention: Bedtime chronotherapy with >/=1 conventional hypertension medications
Number of subjects: 18078

Group type: EXPERIMENTAL
Intervention: Routine diagnosis of hypertension and individualized assessment of CVD and other risks by ABPM
Number of subjects: 18078

Group type: EXPERIMENTAL
Intervention: Composite of CVD death, myocardial infarction, coronary revascularization, heart failure, ischemic stroke, and hemorrhagic stroke
Number of subjects: 18078
Study: 24758484

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with SOX (Ce-SOX)
Number of subjects: 56
Study: 23782955

Group type: EXPERIMENTAL
Intervention: PD 0348292 (0.1 mg qd to 10 mg qd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin (30 mg bid)
Number of subjects: 0
Study: 18996518

Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in low-response patients
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in moderate-response patients
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in high-response patients
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: M-CSF levels in serum throughout stimulation until oocyte retrieval
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: M-CSF levels in pregnant patients post-retrieval
Number of subjects: 95
Study: 18686051

Group type: EXPERIMENTAL
Intervention: Theatrically based intervention (acting lessons, twice a week for 4 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 122

Group type: COMPARATOR
Intervention: Singing (different performing art)
Number of subjects: 122
Study: 16778272

Group type: EXPERIMENTAL
Intervention: Usual rehabilitation (UR) plus electrostimulation (ES) for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual rehabilitation (UR) alone
Number of subjects: 17
Study: 14760341

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Atenolol (50 mg/d)
Number of subjects: 159
Study: 11421145

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music of their choice via audiotapes and headphones before and during simulation and daily treatments)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 42
Study: 9204327

Group type: EXPERIMENTAL
Intervention: Gadopentetate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 7648782

Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Poor metabolic control (increase of HbAlc% levels)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Deterioration of metabolic control
Number of subjects: 46

Group type: COMPARATOR
Intervention: Aging and duration of diabetes mellitus
Number of subjects: 46
Study: 3555607

Group type: EXPERIMENTAL
Intervention: Bandage contact lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study: 31312963

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic system
Number of subjects: 112

Group type: COMPARATOR
Intervention: 2D laparoscopic system
Number of subjects: 112
Study: 29688172

Group type: EXPERIMENTAL
Intervention: nBDP 100 μg per nostril twice daily
Number of subjects: 34
Study: 27482087

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (IN-OT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 24736243

Group type: EXPERIMENTAL
Intervention: Intermediate care clinics for diabetes (ICCDs)
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1997
Study: 24399583

Group type: EXPERIMENTAL
Intervention: High sensitive cardiac troponin-I (HsTn-I) in patients with SCF pattern
Number of subjects: 97

Group type: COMPARATOR
Intervention: Coronary artery disease (CAD) group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Normal coronary arteries
Number of subjects: 97
Study: 20682502

Group type: EXPERIMENTAL
Intervention: Probiotics (VSL #3 and Lactobacillus casei DN‐114 001)
Number of subjects: 0
Study: 19794200

Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 104
Study: 16169430

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12505733

Group type: EXPERIMENTAL
Intervention: Transverse paddle orientation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Longitudinal paddle orientation
Number of subjects: 20
Study: 10389843

Group type: EXPERIMENTAL
Intervention: Cow's milk formula feeding
Number of subjects: 200

Group type: COMPARATOR
Intervention: Exclusively breast-fed
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Children with at least two diabetes‐associated autoantibodies
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 200
Study: 8677586

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of PGE1 at a speed of 60 seconds
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intracavernous injection of PGE1 at a speed of 5 seconds
Number of subjects: 11
Study: 1799761

Group type: EXPERIMENTAL
Intervention: 5-F catheter
Number of subjects: 499

Group type: COMPARATOR
Intervention: 7-F catheter
Number of subjects: 499
Study: 6872421

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31362753

Group type: EXPERIMENTAL
Intervention: H2GO! intervention (community-based youth empowerment intervention)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard programming (control group)
Number of subjects: 110
Study: 28558702

Group type: EXPERIMENTAL
Intervention: 0.05 U/kg AVP under P/R anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05 U/kg AVP under S/N anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous bolus of saline under P/R anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous bolus of saline under S/N anaesthesia
Number of subjects: 60
Study: 26921128

Group type: EXPERIMENTAL
Intervention: Simple debridement (Deb)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biceps tenotomy (BTo)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biceps tenodesis (BTd)
Number of subjects: 86
Study: 22925188

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional closed drainage (TCD)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both VAC and TCD
Number of subjects: 130
Study: 22488817

Group type: EXPERIMENTAL
Intervention: Management with urodynamics (N = 31)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Management without urodynamics (N = 28)
Number of subjects: 59
Study: 19224304

Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg intravenous)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study: 17684992

Group type: EXPERIMENTAL
Intervention: Perfluorane (4 ml/kg body weight) administered within the first 24 hours after injury
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study: 15147801

Group type: EXPERIMENTAL
Intervention: 200 M lactose as carrier for FK888 dry powder inhaler (DPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various carrier lactoses (100 M, 325 M, 200 M, 450 M, micronized lactoses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Micronized lactoses (MLs)
Number of subjects: 0
Study: 11318913

Group type: EXPERIMENTAL
Intervention: Announced standardized patient-instructors (SPIs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unannounced standardized patient-instructors (SPIs)
Number of subjects: 24
Study: 9815809

Group type: EXPERIMENTAL
Intervention: 1, 2, or 4 mg of aluminum hydroxide-precipitated 3H1 anti-idiotype antibody every other week for four injections and then monthly until tumor progression.
Number of subjects: 24
Study: 8185457

Group type: EXPERIMENTAL
Intervention: Seated group exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: Group reminiscence therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and reminiscence)
Number of subjects: 55
Study: 2897515

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin (four doses in two days)
Number of subjects: 0
Study: 30783823

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly data download from insulin pumps and glucometers, immediate phone feedback, face-to-face visits every 6 months)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (routine care with face-to-face visits every 3 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study: 27921216

Group type: EXPERIMENTAL
Intervention: Rumination induction task
Number of subjects: 41

Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 41
Study: 27057904

Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group PEEP (10 cm H2O)
Number of subjects: 50
Study: 24372443

Group type: EXPERIMENTAL
Intervention: Nursing care based on the Theory of Human Caring
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study: 22747353

Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 52

Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 52
Study: 19076790

Group type: EXPERIMENTAL
Intervention: 4.5 MU IFN-alpha2a
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 53
Study: 17329698

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Community-based periodontal care
Number of subjects: 120
Study: 15309972

Group type: EXPERIMENTAL
Intervention: PDRN eye drops
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 60
Study: 11283440

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (lactose capsules)
Number of subjects: 27
Study: 9883463

Group type: EXPERIMENTAL
Intervention: Individuals with more advanced DAT (mildly demented)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very mildly impaired patients with DAT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 0
Study: 7608354

Group type: EXPERIMENTAL
Intervention: Experiential therapy using Gestalt empty‐chair dialogue intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Attention-placebo condition (psychoeducational group)
Number of subjects: 34
Study: 2239758

Group type: EXPERIMENTAL
Intervention: Fish diet (200 g lean Australian fish flesh/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fish diet supplemented with 5 g fish oil/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (essentially fish free)
Number of subjects: 12
Study: 908151

Group type: EXPERIMENTAL
Intervention: 1 mg oral metoclopramide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 5 mg oral metoclopramide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 10 mg oral metoclopramide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 20 mg oral metoclopramide
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31521847

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 199
Study: 28632543

Group type: EXPERIMENTAL
Intervention: SVV guidance
Number of subjects: 42

Group type: COMPARATOR
Intervention: CVP guidance
Number of subjects: 42
Study: 25477161

Group type: EXPERIMENTAL
Intervention: Folate (5 mg)
Number of subjects: 244
Study: 23993772

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Cardiac index
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: PEEP and cardiac index association
Number of subjects: 367

Group type: COMPARATOR
Intervention: Fluid management protocols (liberal or conservative)
Number of subjects: 367
Study: 21176086

Group type: EXPERIMENTAL
Intervention: 600 microg oral misoprostol (n = 534)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Placebo (n = 585)
Number of subjects: 1119
Study: 19409861

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17725473

Group type: EXPERIMENTAL
Intervention: Standardised suctioning procedure followed by a standardised recruitment manoeuvre.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group received only the single suctioning procedure.
Number of subjects: 48
Study: 15465075

Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 26
Study: 11842906

Group type: EXPERIMENTAL
Intervention: 5-N load with oscillation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-N static load
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100-N static load
Number of subjects: 30
Study: 9725663

Group type: EXPERIMENTAL
Intervention: 1‐monoglyceride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: triglyceride
Number of subjects: 6
Study: 7981845

Group type: EXPERIMENTAL
Intervention: Jogging at an intensity of 75% VO2max (n = 28)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Walking at an intensity of 50% VO2max (n = 28)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Jogging (n = 28)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Walking (n = 28)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Inactive control group (n = 19)
Number of subjects: 75
Study: 2247718

Group type: EXPERIMENTAL
Intervention: Estimation of correlation between GFR and inverse serum creatinine slopes
Number of subjects: 0
Study: 603217

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard postoperative physiotherapy (Control)
Number of subjects: 22
Study: 31586377

Group type: EXPERIMENTAL
Intervention: Exercise based on the FITT protocol for 8 weeks
Number of subjects: 86
Study: 28556284

Group type: EXPERIMENTAL
Intervention: Tadalafil plus α1-blocker combination therapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: α1-blocker monotherapy
Number of subjects: 171
Study: 25790672

Group type: EXPERIMENTAL
Intervention: Qiangji Recipe (QR) + Celecoxib Capsule (0.2 g, twice daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Celecoxib Capsule (0.2 g, twice daily)
Number of subjects: 54
Study: 23498169

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg)
Number of subjects: 33
Study: 16467122

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 9000
Study: 12732606

Group type: EXPERIMENTAL
Intervention: Baseline assessment of LV size and function
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: 1 year assessment of LV size and function
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: 2 years assessment of LV size and function
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Changes in LV size and function from baseline to 2 years
Number of subjects: 263

Group type: COMPARATOR
Intervention: ACE inhibitors and beta‐adrenergic receptor blockers
Number of subjects: 263
Study: 10528024

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: beta-carotene (20 mg)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: both alpha-tocopherol and beta-carotene
Number of subjects: 29133

Group type: COMPARATOR
Intervention: neither alpha-tocopherol nor beta-carotene
Number of subjects: 29133
Study: 8702250

Group type: EXPERIMENTAL
Intervention: Circadian rhythm-modulated rate of carboplatin (CBDCA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant rate of carboplatin (CBDCA)
Number of subjects: 24
Study: 1705258

Group type: EXPERIMENTAL
Intervention: Two boluses of GH (2 units administered iv)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eight boluses of GH (2 units administered iv)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Constant infusion of GH (2 units administered iv)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All GH study protocols
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Constant infusion of GH
Number of subjects: 6
Study: 6667034

Group type: EXPERIMENTAL
Intervention: Lead chelating agent
Number of subjects: 0
Study: 30974489

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2961

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2961
Study: 27072591

Group type: EXPERIMENTAL
Intervention: Fish oil-enriched dairy drink (400 mL/day, ±400 mg EPA-DHA/day)
Number of subjects: 110
Study: 25125457

Group type: EXPERIMENTAL
Intervention: 400 mg solanezumab every 4 weeks for 18 months
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 18 months
Number of subjects: 1314
Study: 22677919

Group type: EXPERIMENTAL
Intervention: Reference normal sleep night (RN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 12
Study: 21636120

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tiotropium 10 μg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg and 10 μg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 19330891

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication supply classification (undersupply, appropriate supply, oversupply)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Medication acquisition measures
Number of subjects: 562
Study: 16802768

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 88 microg twice daily
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 44 microg twice daily
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo (chlorofluorocarbon propellant alone)
Number of subjects: 332